Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine in a large, double-blind, randomized, prospective pediatric clinical trial whether the use of continuous levalbuterol (Xopenex) in addition to standard emergency department treatment for acute asthma exacerbations will improve the Forced Expiratory Volume in 1 sec (FEV 1) compared to the use of continuous racemic albuterol. The secondary objective is to correlate clinical (hospitalization rates and clinical asthma scores) with plasma levels of (S)-albuterol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Phoenix Children's Hospital
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• Patient is between the ages of 6 and 17

• Has previously been diagnosed with asthma by any physician

• Has presented to the ED with an asthma exacerbation judged by a physician to be of a moderate or severe degree

Exclusion Criteria:

• Requires immediate resuscitation (attending physician)

• Is pregnant and/or breast feeding

• If possibly pregnant, negative pregnancy test attached

• Has chronic lung diseases (i.e. cystic fibrosis)

• Has an uncorrected congenital heart diseaseHas a suspected foreign body aspiration

• Is allergic to albuterol and/or levalbuterol (Xopenex)

• Has an initial FEV 1>70% predicted